Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 0.83 |
| ▸ | MMP2 | P08253 | 19/20 | 0.83 |
| ▸ | MMP9 | P14780 | 13/20 | 0.83 |
| ▸ | MMP3 | P08254 | 7/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.83 |
| ▸ | MMP12 | P39900 | 1/20 | 0.83 |
| ▸ | MMP14 | P50281 | 1/20 | 0.83 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.83 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.83 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.83 |
| ▸ | MMP1 | P03956 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038872 | 1.00 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL15428480 | 1.00 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366994 | 0.92 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366294 | 0.92 | ADAM10 (0.83) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL17288026 | 0.91 | ADAM10 (0.82) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL4323548 | 0.91 | ADAM10 (0.82) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL209111 | 0.91 | ADAM10 (1.00) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1366486 | 0.91 | ADAM10 (1.00) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL4336513 | 0.90 | ADAM10 (0.70) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL4342726 | 0.90 | ADAM10 (0.68) | ADAM10MMP2MMP9MMP3ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-06-13 | — | — | US | disclosed |
| US-20210010084-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2021-01-14 | — | — | US | disclosed |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2018164518-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND USE THEREOF | 한양대학교 산학협력단 | 2018-09-13 | — | — | WO | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9801877-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2017-02-09 | — | — | US | disclosed |
| US-9345677-B2 | Compositions, methods and kits relating to HER-2 cleavage | INCYTE CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-3020402-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Holdings Corporation (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8637497-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2617419-A1 | Aza spiro alkane derivatives as inhibitors of metallproteases | Incyte Corporation (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120263676-A1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-10-18 | — | — | US | disclosed |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1622569-A4 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1622569-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Corporation (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1613269-A2 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | Incyte Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040247602-A1 | Compositions, methods and kits relating to Her-2 cleavage | INCYTE CORPORATION | 2004-12-09 | — | — | US | disclosed |
| WO-2004096139-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004089294-A2 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210010084-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885MMP9 49/4885 |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
| US-11674182-B2 | Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885MMP9 49/4885 |
| US-20230366035-A1 | BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF | ADAM10, ADAM17, MMP20 | ADAM10 1/4885MMP2 196/4885MMP9 49/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.